Rituximab may benefit patients with early-onset myasthenia gravis
27 May 2020
byAudrey Abella
In patients with nonMuSK+* generalized myasthenia gravis (gMG), early initiation of therapy with the B-cell–depleting monoclonal antibody rituximab may improve treatment outcomes compared with conventional immunosuppressant therapy**, a Swedish retrospective analysis has shown.